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Background   Modern metal-on-metal hip resurfacing was intro-
duced as a bone-preserving method of joint reconstruction for 
young and active patients; however, the large diameter of the 
bearing surfaces is of concern for potentially increased metal ion 
release. 
Patients and methods   71 patients (< 65 years old) were ran-
domly assigned to receive either a resurfacing (R) hip arthroplasty 
(n = 38) or a conventional metal-on-metal (C) hip arthroplasty 
(n = 33). Functional outcomes were assessed preoperatively and 
at 6, 12, and 24 months. Cobalt and chromium blood levels were 
analyzed preoperatively and at 3, 6, 12, and 24 months. 
Results   All functional outcome scores improved for both 
groups. At 12 and 24 months, the median UCLA activity score 
was 8 in the R patients and 7 in the C patients (p < 0.05). At 24 
months, OHS was median 16 in C patients and 13 in R patients 
(p < 0.05). However, in spite of randomization, UCLA scores 
also appeared to be higher in R patients at baseline. Satisfaction 
was similar in both groups at 24 months. Cobalt concentrations 
were statistically significantly higher for R patients only at 3 and 
6 months. Chromium levels remained significantly higher for R 
patients until 24 months. No pseudotumors were encountered in 
either group. One R patient was revised for early aseptic loosen-
ing and in 2 C patients a cup insert was exchanged for recurrent 
dislocation. 
Interpretation   R patients scored higher on UCLA, OHS, and 
satisfaction at some time points; however, as for the UCLA, preop-
erative levels were already in favor of R. The differences, although 
statistically significant, were of minor clinical importance. Chro-
mium blood levels were statistically significantly higher for R 
patients at all follow-up measurements, whereas for cobalt this was 
only observed up to 6 months. The true value of resurfacing hip 
arthroplasty over conventional metal-on-metal hip arthroplasty 
will be determined by longer follow-up and a possible shift of bal-
ance between their respective (dis)advantages.  
Hip resurfacing arthroplasty has been proposed as the best 
treatment option for advanced osteoarthritis of the hip in 
young and active patients, with a component survivorship of 
94% to 99.8% at 3 to 8 years of follow-up (Vail et al. 2006, 
Amstutz et al. 2007). In comparison to conventional total hip 
arthroplasty, it has been claimed that resurfacing has several 
advantages including preservation of femoral bone stock, 
better functional outcomes, and lower rates of dislocation (Vail 
et al. 2006, Lavigne et al. 2010, Smolders et al. 2010). There 
is, however, very little evidence available to support these 
claims. Only a limited number of studies have been published 
in which the clinical results of resurfacing and a conventional 
hip arthroplasty were compared. Most of these studies were 
matched cohort series, since true randomized controlled trials 
(RCT) are difficult to perform. There has been only one RCT 
where the clinical results of resurfacing arthroplasty were 
compared with the clinical results of a 28-mm metal-on-metal 
hip arthroplasty (Vendittoli et al. 2006). Both in that RCT and 
in some of the matched cohort series, a statistically signifi-
cantly better functional score was found in selected outcome 
parameters for resurfacing at short-term follow-up; however, 
the clinical relevance is argued by the authors (Pollard et al. 
2006, Vail et al. 2006, Fowble et al. 2009, Mont et al. 2009). 
In addition, the higher level of activity encountered for resur-
facing hip prostheses in some series applies to both pre-and 
postoperative values (Pollard et al. 2006, Fowble et al. 2009, 
Mont et al. 2009). Another confounding factor, especially in 
the matched cohort series, may also have been the profound 
implant preference in the resurfacing group—which may have 
biased the eventual functional outcome relative to that of a 
conventional hip arthroplasty group (Mont et al. 2009, Bissel-
ing et al. 2011).
In contrast to the potential advantage of a resurfacing, there 
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and systemic metal ion exposure from these implants. It is well 
recognized that hip arthroplasties with a metal-on-metal bear-
ing lead to an increase in blood levels of metal ions, especially 
cobalt and chromium (Back et al. 2005, Antoniou et al. 2008, 
Moroni et al. 2008, Garbuz et al. 2010). High wear from metal 
bearings may cause severe complications such as pseudotu-
mor formation and soft tissue necrosis (Shimmin et al. 2005, 
Keegan et al. 2007, Pandit et al. 2008). In general, one would 
expect higher release of cobalt and chromium from resurfac-
ing, with a relatively large articulating metal-on-metal bear-
ing, as compared to a regular metal-on-metal hip arthroplasty, 
but there have been no conclusions in the literature about this 
issue (Smith et al. 2001).
In the only RCT that has been published (from Canada), 
clinical results of resurfacing were compared to those from a 
conventional 28-mm metal-on-metal hip arthroplasty (Vendit-
toli et al. 2006, 2010). Since the amount of metal ion release 
may play an important role in the eventual outcome and revi-
sion rate of an implant, we decided to perform a similar trial 
comparing resurfacing with a conventional 28-mm metal-on-
metal hip arthroplasty. In contrast to the earlier trial (Vendit-
toli et al. 2010), besides functional outcome we also assessed 
the blood levels of cobalt and chromium for both implants 
with time. In this RCT, we questioned whether the functional 
results of resurfacing would indeed be superior to a conven-
tional metal-bearing hip arthroplasty and whether a large-
diameter resurfacing bearing would induce more release of 
metal ions than a similar but relatively small 28-mm bearing. 
As there is currently a lot of debate in the literature about the 
potential (dis)advantages of resurfacing, we felt that it would 
be appropriate to present the data of our exploratory RCT after 
short-term follow-up.
Patients and methods
Study design and randomization procedure
The present RCT was an exploratory study designed to com-
pare the functional results and metal ion blood levels of 
patients who received a resurfacing total hip arthroplasty (R) 
against those from a conventional uncemented metal-on-metal 
total hip arthroplasty (C) in the short term, medium term, and 
long term.
From June 2007 through January 2010, 82 patients were 
randomly assigned to receive one of the two hip implants (R 
or C). A computer-generated variable block schedule was 
used for randomization. The randomization list was gener-
ated by an independent statistician and the resulting treatment 
allocations were stored in sealed opaque envelopes. Random-
ization occurred at the outpatient consultation by the ortho-
pedic surgeon at the time of planning the hip arthroplasty. 
The patient and surgeon could not be blinded regarding the 
eventual type of implant; neither of them could, however, 
affect the outcome of randomization. The criteria for inclu-
sion were patients under 65 years who needed a primary hip 
replacement for arthritis. Patients were excluded if they had 
had (previous) infection of the hip or at other sites, hip frac-
ture, avascular necrosis with collapse, osteoporotic bone min-
eral density, neoplasm, or renal failure. Inclusion and sub-
sequent follow-up of patients is summarized in Figure 1. A 
per-protocol analysis was used in this study, because revised 
patients cannot be followed for metal ions. 5 patients (3 in the 
R group and 2 in the C group) were lost to follow-up: directly 
after operation (n = 1), after 12 months (n = 3), or after 24 
months (n = 1). 4 patients did not participate in all follow-ups 
because of revision at 12 months (n = 1) or 24 months (n = 2), 
and 1 patient did not attend the 24-month follow-up (Figure 
1). Of the randomized patients, 70 had a minimal follow-up 
of 12 months: 38 patients in the R group, and 32 patients in 
the C group. 
We obtained approval from the regional ethics commit-
tee of Radboud University Nijmegen Medical Center (LTC 
419-071206). All patients agreed to sign an informed con-
sent statement. The study was performed in compliance with 
the Helsinki declaration and has been registered in EudraCT 
(2006-005610-12). 
Surgical technique
All operations were performed by 1 of 3 experienced hip 
surgeons using a posterolateral approach. In the R group, a 
resurfacing prosthesis was implanted with both components 
made of a cast, heat-treated solution-annealed Co-Cr alloy 
(Conserve plus; Wright Medical Technology, Arlington, TN). 
Mean resurfacing femoral head size was 48.7 mm (SD 3.5). 
The femoral component was cemented with low-viscosity 
cement after preparation of the femoral head with multiple 
subchondral anchor holes, and the HA coated cup was press-
fitted into the acetabulum. The surgical technique has been 
described previously (Amstutz et al. 2006). In the C group, 
an uncemented tapered stem and a threaded titanium cup with 
a polyethylene insert with a metal liner was placed (Zwey-
muller Classic; Zimmer Orthopaedics, Warsaw, IN) together 
with a metal 28-mm head (Metasul; Zimmer Orthopaedics). 
Both groups received identical antibiotic prophylaxis with 
Cephalosporine preoperatively and 24 h postoperatively, peri-
articular ossification prophylaxis using Diclofenac for 3 days, 
and thrombosis prophylaxis with fraxiparine during hospital 
admission and until 6 weeks later. Patients were rehabilitated 
with immediate unrestricted weight bearing according to what 
they could tolerate (Hol et al. 2010).
Clinical evaluation
Questionnaires that included the SF-12, Oxford hip 
score (OHS), and VAS implant satisfaction were filled in 
preoperatively and at 6, 12, and 24 months. The Harris hip 
score (HHS) and the University of California at Los Ange-
les (UCLA) activity score were assessed by an independent 
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Blood levels of cobalt and chromium 
Whole blood samples were collected preoperatively and at 3, 
6, 12, and 24 months postoperatively, and assessed for cobalt 
and chromium concentrations. Blood was collected in metal-
free Vacutainers and the first 5 mL was discarded to eliminate 
metal contamination from the needle. Tubes were stored at 
2–8°C and sent to the toxicology laboratory of Ghent Univer-
sity Hospital, Belgium for analysis. The metal ion levels in 
serum and whole blood were determined using an inductively-
coupled plasma mass spectrometer (ICP-MS). Since 9 patients 
(5 in the R group and 4 in the C group) with a bilateral implant 
(Figure 3) had double exposure to wear and thus tended to have 
higher blood levels of metal ions, these data are presented sep-
arately from those of unilateral implants. Extracted data from 
the unilateral group were considered to represent the metal ion 
concentration curves in the R and C groups most reliably. Fol-
lowing the recommendations of Daniel et al. (2007), we only 
report on metal ion levels in whole blood.
Statistics
Metal ion data distributions were asymmetric and are 
expressed as a group median and range. Friedman’s ANOVA 
was used for analysis. To determine the between-time differ-
ences within the groups, we used the non-parametric Wilcoxon 
signed-ranks test. To protect against type-1 error, a Bonfer-
roni correction was applied. To determine differences between 
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Figure 1 . Consort statement – flow chart of participants throughout the study.562  Acta Orthopaedica 2011; 82 (5): 559–566
the two groups and between functional results, we used the 
Mann-Whitney U test. Symmetrical data are represented by 
mean and standard deviation (SD). In box plots, the outliers 
are represented by a dot (•) and extreme outliers (more than 
3 times deviation of the interquartile range from the upper 
quartile) are characterized by an asterisk (*). Differences were 
considered statistically significant at p-values of < 0.05. Lack 
of information about metal ion levels and functional results 
because of patients not participating in all follow-ups, the 
small number of patients, and multiple endpoints made this 
an exploratory trial. The results should therefore be read as 
provisional. Because of the exploratory nature of the study, 
formal adjustment for multiplicity between endpoints was not 
made. All the statistical analyses were performed using SPSS 
software version 17.0.
Results
The patient characteristics, without statistical significant dif-
ferences between the two groups, are given in Table 1. Mean 
follow-up for both groups was 20 months. Of the 71 patients, 
we present a follow-up of 70 at 1 year and of 40 at 2 years. 
Mean operating time was longer for the R group, 77 min as 
opposed to 57 min (p < 0.001). Median blood loss was the 
same for the two groups. 
Clinical evaluation
The clinical scores are summarized in Table 2 and Figure 2. 
In spite of the fact that we performed a randomized trial, the 
preoperative values of UCLA activity score and SF-12 were 
lower in the C group. The HHS, OHS, UCLA activity score, 
and SF-12 all improved after surgery in both groups (p < 
0.001). This improvement in clinical scores remained stable 
throughout the 24-month follow-up. At 6 and 24 months, 
we found a better OHS in the R-group patients than in the 
C-group patients (p = 0.04, r = –0.33). The median UCLA 
activity score was better for the R-group patients at all three 
time points with medium effect size (6 months: p = 0.01, r = 
–0.30; at 12 months: p = 0.002, r =–0.38; and at 24 months: 
p = 0.04, r = –0.32). At 24 months, there was one negative 
outlier in the C group with a UCLA activity score of 2. This 
patient has a contralateral hip arthritis, which may explain his 
low activity score since his satisfaction score for the operated 
side was 98/100. R-group patients were more satisfied after 
12 months than C-group patients (p = 0.01, r = –0.30); this 
difference remained but was not statistically significant at 24 
months. 
Since we encountered statistically significantly better 
functional scores for R-group patients at some time points, 
including the preoperative one, we also compared the actual 
improvement in score between groups. In this analysis, sta-
tistically significant differences in actual improvement in the 
various clinical scores could no longer be detected. 
Blood levels of cobalt and chromium
The concentrations of chromium and cobalt in whole blood 
of patients in the R and C groups for each time point are sum-
marized in Table 3 and Figure 3. As expected, baseline pre-
operative chromium and cobalt concentrations were below 
the reference level of 1.0 µg/L for patients with a unilateral 
implant (both groups) (Mayo Medical Laboratories 2010). 
Blood cobalt and chromium levels increased (p < 0.001) in 
both groups after surgery until 6 months postoperatively, with 
stable concentrations thereafter. Cobalt concentrations were 
higher for R-group patients than for C-group patients only at 
3 months (p < 0.001, r = –0.50) and 6 months (p = 0.006, r = 
–0.35). Cobalt levels stabilized after 6 months in the R group, 
and the initially statistically significant difference between 
groups could no longer be detected at 12 months (p = 0.1) 
Table 1. Patient characteristics 
  R C
  (n = 38)  (n = 33)
Median age in years (range)  58 (24–65)  59 (37–65)
Mean body mass index (SD)   26 (3.1)  28 (5.1)
Sex ratio (men:women)   21:17  21:12
Uni- or bilateral MoM prosthesis  33:5  29:4
Diagnosis (OA/AVN/CHD) a 35/1/2  31/0/2
Charnley category (A/B)  24/14  23/10
 
a OA: osteoarthritis; AVN: avascular necrosis; CHD: congenital hip 
   dysplasia.
Table 2. Clinical scores and satisfaction (VAS), values are median (range)
  Preoperatively  12 months  24 months 
  R C  R  C  R C
  (n = 38)  (n = 33)  (n = 38)  (n = 32)  (n = 19)  (n = 21)
Harris hip score  57 (28–77)  53 (25–82)    98 (60–100)    96 (49–100)    96 (63–100)    95 (47–100)
UCLA activity     5 (2–10) b    4 (2–8) b      8 (4–10) b       7 (2–9) b        8 (5–10) b       7 (2–10) b
SF-12  88 (59–112) b  79 (55–113) b  107 (71–116)  107 (51–117)  110 (69–117)  110 (51–133)
Oxford hip score  34 (20–46)  37 (21–44)    13 (12–31)    15 (12–40)    13 (12–34) b    16 (12–37) b 
VAS satisfaction  89 (49–100) a  82 (10–100) a    92 (52–100) b    85 (12–100) b    92 (37–100)    89 (15–100) 
a VAS satisfaction: 6-month value. 
b Significant difference between resurfacing (R) and conventional (C) hip arthroplasty (p ≤ 0.05).Acta Orthopaedica 2011; 82 (5): 559–566  563
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and 24 months (p = 0.1). Chromium concentrations were also 
higher in the R group, but this time at all time points until 24 
months and with a large effect size (p < 0.001, r = –0.50). We 
could not establish any correlation between metal ion concen-
tration and gender, femoral component diameter, or age.
4 patients (3 in the R group and 
1 in the C group) had extremely 
high levels of metal ions at 12 and 
24 months (Figure 3). At these time 
points they had good clinical scores 
with HHS of 98 (95–100), OHS of 13 
(12–16), and a median UCLA activity 
score of 6.5 (6–8). These patients will 
be monitored closely. 
The subgroup of bilateral metal-
on-metal implants did not have sta-
tistically significantly higher metal 
ion concentrations than the unilateral 
group, but it should be noted that the 
bilateral subgroup was small (Table 
3). One extreme outlier of cobalt 
with a concentration of 10.6 µg/L 
at 12 months was encountered in a 
male (R-group) patient with a bilat-
eral implant. This patient had a high 
UCLA activity score of 9, HHS of 98, 
and an excellent satisfaction score of 
95/100.  There were no statistically 
significant differences between unilat-
eral and bilateral prostheses regarding 
cobalt levels (p = 0.2) and chromium 
levels (p = 0.8) at 12 months.
Complications 
There were 3 C-group patients with 
recurrent dislocation, for which 2 
patients had an early re-intervention 
with cup insert and head exchange, 
and there were no dislocations after-
wards. In addition, 2 early deep infec-
Figure 2. A. Boxplot of Harris hip score. B. Boxplot of UCLA activity score. C. Boxplot of SF-12. D. 
Boxplot of Oxford hip score. a Significant differences between the R and C groups.
tions were encountered in the C group without recurrence of 
infection after lavage. In the R group, one early revision was 
encountered; an early aseptic loosening from avascular necro-
sis of the femoral head dictated conversion to an intramedul-
lary stem with a large femoral head. The metal acetabular cup 
Table 3. Whole-blood cobalt and chromium concentrations, values (µg/L) are median (range)
  Preoperative  6 months  12 months  24 months
 R C  R  C  R C  R  C
Unilateral implants
     (n=33)     (n=29)     (n=33)     (n=29)     (n=33)     (n=28)     (n=16)     (n=17)
Co  0.1 (0.1–0.8)  0.1 (0.1–0.6)  1.3 (0.1–23) a  0.85 (0.1–4.0) a  1.25 (0.6–8.3)  1.0 (0.1–4.2)  1.2 (0.5–22)  0.9 (0.1–2.7)
Cr  0.1 (0.1–1.4)  0.1 (0.1–0.1)  1.1 (0.1–15) a  0.1 (0.1–2.9) a  1.0 (0.1–6.1) a  0.5 (0.1–2.0) a  1.2 (0.1–10) a  0.5 (0.1–2.1) a
Bilateral implants
     (n=5)     (n=4)     (n=5)     (n=4)     (n=5)     (n=4)     (n=3)     (n=4)
Co  0.3 (0.1–1.1)  0.1 (0.1–1.8)  1.7 (1–7.9)  0.85 (0.5–2.2)  1.9 (0.9–11)  1.15 (0.8–1.3)  2.0 (0.7–6.0)  1.4 (0.7–1.8)
Cr  0.1 (0.1–0.9)  0.1 (0.1–0.8)  1.7 (0.1–3.8)  0.25 (0.1–1.5)  2.2 (0.1–4.9)  0.5 (0.1–0.8)  1.5 (0.1–2.3)  0.75 (0.6–0.8)
a Significant difference between resurfacing (R) and conventional (C) hip arthroplasty (p ≤ 0.05).
A
C
B
D
a
a a
a
a
a a
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was kept since the patient had been pain-free for 2 years and 
the whole-blood cobalt level was 2.3 µg/L prior to revision. 
Discussion
The most important findings of this exploratory study were 
that after 1 and 2 years, chromium concentrations were higher 
in patients with resurfacing hip arthroplasty, and cobalt con-
centrations were comparable with those in patients with a 
conventional arthroplasty. The functional results improved 
substantially in both groups without any major differences 
between groups.
The functional results—tested by validated functional 
scales—showed a highly significant postoperative improve-
ment in both groups, which is in line with other studies (Pol-
lard et al. 2006, Vail et al. 2006, Fowble et al. 2009, Mont et 
al. 2009, Garbuz et al. 2010, Lavigne et al. 2010, Stulberg 
et al. 2010, Vendittoli et al. 2010). A limitation of some of 
these studies was that the preoperative values of the resurfac-
ing group were different from those in the control group (Vail 
et al. 2006, Fowble et al. 2009, Mont et al. 2009). In our RCT, 
this confounding factor was not apparent, as the preoperative 
HHS and OHS values were similar. In spite of the randomized 
nature of the present study, the preoperative UCLA activity 
score and SF-12 score were higher in the R-group patients. 
The preoperative values of the SF-12 in the C group were 
lower, and the mental part of the SF-12 accounted for this dif-
ference. The difference in preoperative SF-12 is difficult to 
explain; perhaps the C patients were less satisfied with the 
implant allocated to them. Obtaining the SF-12 result before 
informing the patient about the implant allocated to him or 
satisfaction by VAS at 12 months favored the R group; how-
ever, this difference was inapparent at the 24-month follow-
up. The OHS was also significantly better in the R group at 
6 and 24 months, with a medium effect size, whereas there 
was no significant difference in the preoperative baseline 
levels. The UCLA activity score was significantly higher for 
the R group at each time point until 24 months, however, it 
has been noted that this difference also already applies for 
the preoperative scores, despite the randomization procedure. 
These findings correspond to those in earlier studies. From 
their large, retrospective comparative study Stulberg et al. 
(2010) reported an initial advantage in HHS from resurfacing 
at 6 and 12 months, but the results were comparable after 24 
months. Higher UCLA activity scores after 5–7 years were 
also described for resurfacing in another matched cohort study 
with C-group patients (Pollard et al. 2006). There has only 
been one other RCT comparing resurfacing with conventional 
metal-on-metal hip arthroplasty (Vendittoli et al. 2006). The 
authors also reported initial UCLA activity scores in favor of 
the R group. However, in a recent 3–6-year follow-up report 
of the same study, the statistical significance of this differ-
ence was no longer apparent (Vendittoli et al. 2010). In their 
matched control study, Mont et al. (2009) also found a sig-
nificantly better activity level after 3 years, and no significant 
differences in HHS and satisfaction. They claimed that the 
activity scores were influenced by higher baseline levels and 
selection bias from targeted choice of implant. Selection bias 
was excluded in our study by randomization; however, patient 
outcome can still be influenced by patients having received 
their “preferred” implant. 
With 3 patients having a re-intervention, the percentage of 
early revision in this study was 4%. Of these 3 patients, 2 in 
her could perhaps have prevented this 
confounding variable. This idea is 
also supported by our experience that 
inclusion for randomization proved 
to be extremely difficult. Generally 
speaking, patients tended to prefer a 
resurfacing arthroplasty. It was only 
after considerable explanation that 
we managed to include 82 patients. 
The difficulty we encountered in per-
forming a well-designed RCT was 
also illustrated by the relatively high 
number of exclusions after random-
ization in the C group; 4 patients still 
decided to have further treatment at 
another hospital and withdrew from 
the study after having been allocated 
to total hip arthroplasty.
Some functional outcome scores 
showed a statistically significant dif-
ference in favor of the R group at 
certain time points. For example, 
Figure 3 . A. Boxplot cobalt concentrations of unilateral prosthesis in blood in µg/L. Two extreme 
outliers are not represented for clarity purposes, this concerns two R patients at 6 and 24 months 
with cobalt concentration of respectively 22.80 and 22.00 µg/L. 
   B. Boxplot chromium concentrations of unilateral prosthesis in blood in µg/L. One extreme outlier 
was not represented for clarity purposes, this concerns a R patient at 6 months with a chromium 
concentration of 14.90 µg/L. 
a Significant differences between the R and C groups.
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the C group underwent a relatively simple insert exchange 
for recurrent dislocation and 1 R-group patient had a femoral 
component revision because of early aseptic loosening from 
avascular necrosis. 3 patients in the C group of 33 patients suf-
fered a dislocation, which is an unusually high percentage. We 
do not have a clear explanation for this phenomenon, and do 
not recognize this high number from our own practice/expe-
rience. In 2 patients, a stabilizing insert exchange was per-
formed after CT scanning had revealed proper implant posi-
tioning; no dislocations occurred after this exchange of insert.
Besides functional results as a measurement of postopera-
tive outcome, determination of metal ion levels is becoming 
increasingly common after metal-on-metal arthroplasties and 
serves as an indicator of bearing performance and device 
safety (Back et al. 2005). High metal ion concentrations may 
lead to adverse biological reactions including local soft tissue 
toxicity; hypersensitivity reactions; impaired renal, endocrine, 
and immune function; bone loss; and risk of carcinogenesis 
(Shimmin et al. 2005, Keegan et al. 2007). In the present 
study, initially, resurfacing gave a larger increase in cobalt 
and chromium concentrations than a 28-mm metal bearing hip 
arthroplasty. After their respective run-in phases, cobalt blood 
levels were similar between the two groups at 12 months. Only 
chromium blood levels remained statistically significantly 
higher in the R group at all time points. Since cobalt is known 
to be relatively toxic compared to chromium, it is important 
to have established that blood cobalt levels (specifically) sta-
bilize after a run-in phase of 6 months, and that the difference 
in blood levels with the C group in this study could only be 
established during the first 6 months of follow-up. As com-
pared to most of the published case-controlled or retrospec-
tive reports (Back et al. 2005, Antoniou et al. 2008, Moroni 
et al. 2011) on the performance of several types of resurfac-
ing implants, the metal ion levels after unilateral resurfacing 
in our study appeared to be rather low—with median blood 
levels of cobalt of 1.3 µg/L and of chromium of 1.2 µg/L. This 
observation may be an implant-related phenomenon. 
The relationship between relatively high metal ions and the 
need for revision surgery after resurfacing has already been 
explored (De Smet et al. 2008). In spite of this recognized 
association between elevated cobalt and chromium levels in 
blood and malfunctioning implants, there is limited informa-
tion about the range of acceptable metal ion concentrations 
and where toxicity is introduced. The best-defined reference 
values are the “exposure equivalent of carcinogenic sub-
stances” (EKA values) (Morgan and Schaller 1999) for indus-
trial workers and those in the Mayo Medical Laboratories 
interpretive handbook (Mayo Medical Laboratories 2010). 
The EKA upper limits for cobalt have been defined to be 5 
µg/L in whole blood and those for chromium to be 17 µg/L 
in erythrocytes (as no whole blood upper limits have been 
reported). From their own clinical series with malfunction-
ing resurfacing implants, De Smet et al. (2009) proposed an 
upper acceptable limit of 4.4 µg/L for cobalt and 5.15 µg/L 
for chromium in serum. The median ion levels in the present 
study were well below this limit, although a few outliers were 
encountered. Since a strong correlation between high metal 
ion concentrations and component wear has been established, 
forthcoming early revisions can still be expected in our group 
of patients with longer follow-up (De Smet et al. 2008).
On theoretical grounds (Smith et al. 2001), the wear of 
small- and large-diameter bearings—and therefore the metal 
ion concentrations—should be equal. In the present study, this 
applied to cobalt, but not to chromium. This is partially con-
sistent with results from the literature (Antoniou et al. 2008, 
Moroni et al. 2008). The medium-term follow-up of Moroni et 
al. (2008) showed that after 5 years there were no differences 
in metal ion concentrations between large-diameter resurfac-
ing hip arthroplasty and small-diameter metal-on-metal hip 
arthroplasty. Differences found at 3 and 6 months between R 
patients and C patients (28-mm) for cobalt—and at all time 
intervals for chromium—may be attributed to a run-in phase. 
Interestingly, the run-in phase of the small-diameter head 
in hip arthroplasty appeared to be longer, with a peak at 12 
months, while the large-diameter head concentrations peaked 
at 6 months and stabilized thereafter. 
In conclusion, we believe that the results of our study are 
supported by the only other published RCT comparing resur-
facing with a 28-mm conventional hip arthroplasty (Vendittoli 
et al. 2010). The strength of our study compared to that study 
is that we combined clinical follow-up with prospective evalu-
ation of metal ion levels. In addition, 2 independent RCTs 
with comparable outcome lead to an increase in the level of 
evidence of the findings. On the other hand, there are also 
clear limitations to our study. Inclusion of patients proved to 
be extremely difficult, and the number of patients available 
was therefore limited. Due to the limited number of patients, 
we can only present our data as an exploratory trial, mainly 
because it had insufficient power to allow us to draw firm con-
clusions, but also because the report deals with a short-term 
follow-up. Especially in the light of reports in the literature 
on a peak in revisions after resurfacing at 3 years of follow-up 
(De Smet et al. 2008), we can expect that more revisions in 
the R group will appear. Also, from the fact that at 24 months 
after surgery we encountered some clinically well functioning 
resurfacings with relatively high levels of metal ions, these 
patients may still become symptomatic in the near future and 
the revision rate may increase. We will continue to monitor 
these patients with repeated metal ion measurements and 
functional assessment. Longer follow-up of these two groups 
of patients may help us to understand the potential advantages 
and disadvantages of resurfacing compared to conventional 
arthroplasty. 
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